Your browser doesn't support javascript.
loading
Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP).
Tichy, Martin; Kojanova, Martina; Velackova, Barbora; Dolezal, Tomas; Gkalpakiotis, Spyridon; Cetkovska, Petra.
Afiliación
  • Tichy M; Department of Dermatology and Venereology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
  • Kojanova M; Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
  • Velackova B; Value Outcomes, Prague, Czech Republic.
  • Dolezal T; Value Outcomes, Prague, Czech Republic.
  • Gkalpakiotis S; Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic.
  • Cetkovska P; Department of Dermatovenereology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.
Dermatol Ther ; 35(10): e15772, 2022 10.
Article en En | MEDLINE | ID: mdl-36065488
The IL-17 cytokine family encompasses six different homodimers and heterodimers referred to as IL-17A-F. Due to some differences in the mechanism of IL-17 inhibition, aninsufficient effect of one IL-17 inhibitor does not necessarily imply lack of efficacy of the other agent of the same class. Aim of study was analysis of the success rate of switches among IL-17 inhibitors (secukinumab, ixekizumab, and brodalumab) in patients treated in the Czech Republic. Data were obtained from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP). Our analysis involved data of a total of 90 patients with severe chronic plaque psoriasis and baseline PASI scores >10 both prior to first-line biological therapy initiation and after switch to another agent of the class of IL-17 inhibitors. The most effective switch was that from secukinumab to brodalumab, with PASI 90 reached by 64.7% and 73.3% of patients at weeks 12 and 24. Among patients switched from secukinumab to ixekizumab target PASI 90 responses were achieved (at weeks 12 and 24) by 41.2% and 55.2% of patients. Among patients switched from ixekizumab to brodalumab target PASI 90 responses were achieved, at the above time points, by 30.8% and 38.5% of patients. Our analysis showed a high success rate of switches from secukinumab to ixekizumab and brodalumab, followed by the ixekizumab-to-brodalumab switch. Importantly, the therapeutic response and success rates of individual switches are independent of the patient's body weight and presence of psoriatis arthritis.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Interleucina-17 Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Dermatol Ther Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: República Checa Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Interleucina-17 Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Dermatol Ther Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: República Checa Pais de publicación: Estados Unidos